Mechanotransduction Abnormalities in Skeletal Degeneration: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Mechanotransduction, the process by which cells sense and respond to mechanical stimuli, is fundamental for maintaining skeletal integrity. Disruption of this process has been increasingly recognized as a key driver of skeletal degeneration, including osteoporosis and osteoarthritis. Recent advances in molecular biology and biomechanics have uncovered intricate pathways that link mechanical cues to cellular responses in bone and cartilage. This review synthesizes current evidence regarding mechanotransduction abnormalities in skeletal degeneration, explores clinical presentations, discusses diagnostic approaches, and evaluates established and emerging therapeutic strategies. Emphasis is placed on the translational significance of these mechanisms, providing clinically relevant insights for practitioners managing skeletal disorders.

Introduction

The human skeleton is a dynamic organ system, continually adapting to mechanical forces through the process of mechanotransduction. This phenomenon enables bone and cartilage to remodel in response to physical activity, injury, and aging. However, abnormalities in mechanotransduction can precipitate pathological remodeling, leading to skeletal degeneration. Understanding the molecular and cellular basis of these abnormalities is critical for developing targeted interventions. This article reviews the current landscape of mechanotransduction in skeletal health and disease, with a focus on clinical implications and future therapeutic opportunities.

Epidemiology / Disease Burden

Skeletal degenerative diseases, notably osteoporosis and osteoarthritis, represent a substantial global health burden. Osteoporosis affects over 200 million individuals worldwide, contributing to millions of fractures annually, while osteoarthritis remains the leading cause of disability among older adults. The prevalence of these conditions is projected to rise with population aging and increasing sedentary lifestyles. Mechanotransduction defects have been implicated in both primary and secondary forms of skeletal degeneration, underscoring the importance of early recognition and intervention in at-risk populations.

Pathophysiology

Mechanotransduction involves the conversion of mechanical signals into biochemical responses, primarily mediated by osteocytes, chondrocytes, and their associated extracellular matrices. In healthy bone, mechanical loading stimulates osteocyte signaling pathways such as Wnt/β-catenin, integrins, and ion channels including Piezo1 and TRPV4 that regulate bone formation and resorption. In cartilage, chondrocyte mechanosensors modulate the balance between anabolic and catabolic activity. Abnormalities in these pathways whether due to genetic defects, altered mechanical environment, or age-related changes disrupt cellular homeostasis, leading to decreased bone density, impaired repair, and progressive cartilage breakdown. Notably, reduced mechanical loading (e.g., immobilization, microgravity) accelerates bone loss, while abnormal overloading can precipitate joint degeneration.

Risk Factors

Multiple risk factors augment the likelihood of mechanotransduction abnormalities in skeletal degeneration. Genetics play a substantial role, with polymorphisms in genes encoding mechanosensitive proteins (e.g., LRP5, SOST, PIEZO1) linked to altered skeletal responses. Aging diminishes cellular mechanosensitivity due to decreased expression of key signaling molecules and impaired cytoskeletal dynamics. Other modifiable factors include immobility, chronic inflammation, glucocorticoid exposure, and metabolic diseases such as diabetes, all of which can impair mechanotransduction and precipitate skeletal degeneration.

Clinical Features

Patients with mechanotransduction-associated skeletal degeneration often present with insidious onset of symptoms. Osteoporosis typically manifests as fragility fractures, height loss, and chronic pain, whereas osteoarthritis presents with joint pain, stiffness, reduced mobility, and, in advanced stages, deformity. Early stages may be asymptomatic, highlighting the importance of recognizing risk factors and subtle clinical signs. Family history, rapid loss of function, or atypical presentation should prompt consideration of underlying mechanotransduction defects.

Diagnosis

Diagnosis of skeletal degeneration secondary to mechanotransduction abnormalities requires a multifaceted approach. Clinical assessment is complemented by imaging modalities such as dual-energy X-ray absorptiometry (DXA) for bone mineral density, and MRI or ultrasound for cartilage evaluation. Recent advances permit assessment of bone quality and microarchitecture using high-resolution peripheral quantitative computed tomography (HR-pQCT). Biomarkers reflecting bone turnover and mechanosensitive signaling (e.g., sclerostin, DKK1) are emerging as adjuncts for risk stratification and monitoring therapeutic response. Genetic testing may be considered in select cases with suspected hereditary mechanotransduction disorders.

Treatment & Management

Management strategies target the underlying mechanotransduction pathways to restore skeletal integrity. For osteoporosis, weight-bearing exercise and physical therapy enhance physiological mechanical loading, while pharmacologic agents such as bisphosphonates, denosumab, and anabolic therapies (teriparatide, abaloparatide) modulate bone remodeling. Osteoarthritis management emphasizes joint preservation through load modification, physical therapy, and intra-articular therapies. Emerging approaches include targeting the Wnt/β-catenin pathway or modulating sclerostin and other mechanosensitive mediators to enhance bone and cartilage repair. Multidisciplinary care is essential, particularly in patients with complex comorbidities or refractory disease.

Recent Advances / Emerging Therapies

Recent breakthroughs in mechanobiology have identified novel therapeutic targets. Sclerostin inhibitors (e.g., romosozumab) have demonstrated efficacy in increasing bone formation and reducing fracture risk by enhancing mechanotransduction. Modulation of mechanosensitive ion channels, such as Piezo1 agonists, is under investigation for promoting osteogenesis. In osteoarthritis, agents targeting inflammatory and catabolic pathways downstream of aberrant mechanotransduction show promise. Tissue engineering strategies combining mechanical stimulation with stem cell therapy are being explored for cartilage regeneration. Ongoing clinical trials are expected to refine the safety and efficacy of these interventions, offering hope for disease modification in skeletal degeneration.

Guideline Recommendations

Current clinical guidelines emphasize early identification and risk assessment of individuals susceptible to skeletal degeneration, with particular attention to those with known or suspected mechanotransduction abnormalities. The integration of exercise interventions, nutritional support (adequate calcium and vitamin D), and pharmacotherapy is strongly recommended. For osteoarthritis, guidelines advocate for individualized management, incorporating mechanical load modification and evidence-based pharmacologic agents. Genetic counseling and specialized testing may be appropriate in select cases. As new therapies targeting mechanotransduction become available, guidelines will need to evolve to incorporate these advances in routine clinical practice.

Conclusion

Abnormalities in mechanotransduction are central to the pathogenesis of skeletal degeneration. Advances in understanding the molecular mechanisms underlying these processes are transforming clinical practice, with emerging therapies offering targeted disease modification. Early recognition and intervention, informed by guideline-based approaches, are essential for optimizing outcomes. Continued research and multidisciplinary collaboration will be critical in translating mechanobiological discoveries into improved patient care for those affected by osteoporosis, osteoarthritis, and related skeletal disorders.